$SCMP News
Last published 2y ago
- 2y agoFREQURGNVYGRSCMP+1NorthStar Appoints Peter Pfreundschuh to Board of ManagersBusiness WireNorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer
- 4y agoAUTLGANXSCMPGain Therapeutics Announces Promotion of Matthias Alder to Chief Executive OfficerGlobeNewswireBETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric b
- 10y agoSCMPSucampo Pharmaceutical's (SCMP) CEO Peter Greenleaf on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoSCMPSucampo Pharmaceuticals (SCMP) Q4 2015 Results - Earnings Call WebcastEarnings Call Transcripts
- 13y agoSCMPABTSucampo and Abbott Announce Launch of AMITIZA in JapanBusiness WireBETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Abbott (NYSE: ABT) today announced the availability of AMITIZA® (lubiprostone) in Japan, a prescription medicine for the treatment of chronic constipation not caused by organic diseases. AMITIZA was approved by the Ministry of Health, Labor and Welfare (MHLW) in Japan in June.
- 14y agoSCMPABTSucampo and Abbott Announce Approval for AMITIZA® in JapanBusiness WireBETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Abbott (NYSE:ABT) today announced that Sucampo Pharma, Ltd., a wholly owned subsidiary of SPI, has received approval from the Ministry of Health, Labor and Welfare in Japan for AMITIZA® (lubiprostone), a prescription medicine for the treatment of chronic constipation (excluding constipation c ...
- 15y agoSCMPABTPhase 3 Clinical Trial Data of Lubiprostone in Japanese Patients with Chronic Idiopathic Constipation Presented at DDW 2011Business WireBETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP) and Abbott (NYSE: ABT) today reported data from a phase 3 clinical efficacy trial in 124 Japanese chronic idiopathic constipation (CIC) patients as well as from a phase 3 long-term safety trial in an additional 209 Japanese CIC patients. The purpose of the studies was to confirm the treatme ...